Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Glucocorticoid Therapy and Cushing Syndrome

  • Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Stephen Kemp, MD, PhD  more...
 
Updated: Dec 11, 2015
 

Background

Cushing syndrome (CS) takes its name from Harvey Cushing, who, in 1912, was one of the first physicians to report a patient affected with excessive glucocorticoid.[1] More than 99% of cases of Cushing syndrome are due to administration of excessive amounts of glucocorticoid. This article discusses issues relating to both endogenous and exogenous glucocorticoid excess, with emphasis on the safest possible therapeutic use of glucocorticoids.

Although distinguishing endogenous from exogenous Cushing syndrome is usually straightforward, the investigation and differentiation of Cushing syndrome from other causes of hypercortisolism require a sound understanding of the physiology of the hypothalamic-pituitary-adrenal (HPA) axis. See the images below.

Diagnosis of Cushing syndrome. Diagnosis of Cushing syndrome.
Etiology of Cushing syndrome. Etiology of Cushing syndrome.
Next

Pathophysiology

Glucocorticoid synthesis and release is strictly regulated by the pituitary and hypothalamus by negative feedback and, to a lesser extent, by catecholamines from the adrenal medulla and neural inputs from the autonomic system. In addition to the glucocorticoid effects that cortisol has because of binding to the glucocorticoid receptor (GR), cortisol can also bind to and activate the mineralocorticoid receptor (MR). When cortisol binds to the kidney, MR is physiologically inhibited by conversion of cortisol to its inactive metabolite cortisone by the enzyme 11beta-hydroxy-steroid dehydrogenase (11beta-OHSD2), which co-localizes with the MR.

The basal daily rate of cortisol secretion is approximately 6-8 mg/m2 body surface area, although this can increase as much as 10-fold in response to acute severe stress. Physiological replacement of cortisol requires higher doses of 10-15 mg/m2 because the oral bioavailability is 50-60%. Other natural and synthetic glucocorticoids are noted, all of which have different relative potencies as glucocorticoids and mineralocorticoids because of their differing structures and affinities for the GR and MR, as well as for 11beta-OHSD2. Table 1 summarizes the relative potencies and half-lives of main steroid hormones.

The glucocorticoid receptor is an intracellular protein that, in its ligand-bound form, acts as a nuclear transcription factor to regulate the expression of a diverse array of genes in many areas of the body. Factors that influence the spectrum of adverse effects observed in hypercortisolemic individuals include duration of treatment, potency of the steroid, dose and route of administration, and the site and rate of metabolism and clearance.

Since the late 1940s, when glucocorticoids first came into use for their anti-inflammatory and immunomodulatory effects, much work has been conducted by science and industry to maximize their beneficial effects while minimizing their adverse effects. Thus, many synthetic compounds with glucocorticoid activity have been manufactured and tested.

Alterations of the basic steroid nucleus and its side groups give rise to the pharmacologic differences between these chemicals. Such changes may affect the bioavailability of these steroid compounds, including their GI absorption; parenteral distribution; plasma half-life; their metabolism in the liver, fat, or target tissues; and their ability to interact with the GR and MR and modulate the transcription of glucocorticoid-responsive genes. In addition, structural modifications can diminish the natural cross-reactivity of glucocorticoids with the MR, eliminating their undesirable salt-retaining activity. Other modifications enhance their water solubility for parenteral administration or reduce their water solubility to enhance topical potency.

Most synthetic glucocorticoids (eg, methyl-prednisolone, dexamethasone) are minimally bound to cortisol-binding globulin and circulate freely, or they are weakly bound to albumin. A relatively constant percentage of synthetic glucocorticoids is bound to plasma proteins, and, because this percentage is concentration independent, the rate of metabolic clearance remains constant for synthetic glucocorticoids, regardless of dose. Table 1 shows the relative glucocorticoid and mineralocorticoid potencies of different, commonly used systemic glucocorticoids and their approximate plasma and biologic effect half-lives.

Glucocorticoid activity has been defined mostly in rat bioassays, which may not always reflect human responses, particularly the growth-suppressing properties of synthetic glucocorticoids, which have been markedly underestimated. Glucocorticoids can be categorized as short, intermediate, or long acting, based on their biologic effective half-life, which is defined as the duration of corticotropin (ACTH) suppression after a single dose of the compound.

Table 1. Glucocorticoid Equivalencies[2] (Open Table in a new window)

Type Drug Dose Relative Glucocorticoid Potency Relative Mineralocorticoid Potency Plasma Half-Life



(mg)



Biologic Half-Life



(h)



Short-acting Cortisol 20 1.0 2 90 8-12
Hydrocortisone 25 0.8 2 80-118 8-12
Intermediate-acting Prednisone 5 4 1 60 18-36
Prednisolone 5 4 1 115-200 18-36
Triamcinolone 4 5 0 30 18-36
Methylprednisolone 4 5 0 180 18-36
Long-acting Dexamethasone 0.5 25-50 0 200 36-54
Betamethasone 0.6 25-50 0 300 36-54
Mineralocorticoid Aldosterone 0.3 0 300 15-20 8-12
Fludrocortisone 2 15 150 200 18-36
Desoxycorticosterone acetate 0 0 20 70
Previous
Next

Endogenous Cushing syndrome

Cushing syndrome can be divided into ACTH-dependent and ACTH-independent forms. The proportion of adrenal and pituitary disease varies in different regions; however, in Western countries, 90-95% of cases of Cushing syndrome in children older than 5 years are ACTH-dependent, and 90-95% of those cases are due to Cushing disease caused by an ACTH-secreting pituitary adenoma. Tumors that ectopically secrete ACTH are rare, and tumors that secrete corticotropin-releasing hormone (CRH) are extremely rare, together accounting for fewer than 5% of cases of Cushing syndrome.

In children younger than 5 years, the proportion of ACTH-independent cases of Cushing syndrome approaches 50%. Such cases are due to a combination of congenital disorders of the adrenal cortex and adrenocortical neoplasms that result in autonomous overproduction of cortisol and other adrenal cortical hormones (summarized below). All children in this age group who have been proven to have ACTH-independent Cushing syndrome require adrenalectomy because of the significant incidence of malignancy in this age group.

Pathophysiology of ACTH-dependent Cushing syndrome

Relative frequency is as follows:

  • Age younger than 5 years - 50% of Cushing syndrome cases
  • Age older than 5 years - 80-90% of Cushing syndrome cases

ACTH-producing pituitary adenoma (corticotropinoma) represents 80-90% of ACTH-dependent Cushing syndrome cases in people of all ages. It is usually a microadenoma and may invade the cavernous sinus. It is associated with a risk of Nelson syndrome after bilateral adrenalectomy

Ectopic ACTH production is very rare in children. Ectopic ACTH production is from carcinoid tumors (bronchial tumors most frequent, although may also be in GI tract), ACTH-producing pancreatic islet cell tumors (especially multiple endocrine neoplasia type 1 [MEN1]), pheochromocytoma, ganglioneuroma or other neuroendocrine tumor.

Ectopic CRH production is extremely rare.

Pathophysiology of ACTH-independent Cushing syndrome

Frequency is as follows:

  • Age younger than 5 years - 50% of Cushing syndrome cases
  • Age older than 5 years - 10-20% of Cushing syndrome cases

Adrenocortical neoplasms have a risk of malignancy significant in young children.

Macronodular disease is very rare in children.

Ectopic expression of receptors on cortisol-producing cells, resulting in hypercortisolemia shown in some cases[3]

Micronodular disease may include the following:

  • Primary pigmented nodular adrenal disease (PPNAD)
  • Carney complex (See Table 3.)

McCune-Albright syndrome may be present. See the discussion of McCune-Albright syndrome in Table 3.

Previous
Next

Epidemiology

Frequency

United States

Cushing syndrome is a rare disorder, with 90% of cases occurring during adulthood. Overall incidence is estimated to be 2 new cases per million population per year. Incidence in children is estimated at approximately 0.2 cases per million population per year.

The National Cancer Institute (NCI) estimates the incidence of adrenal cortical carcinoma as 2 cases per million population per year. Pituitary causes of Cushing disease are 5-6 times more common than adrenal causes.

Prevalence of exogenous Cushing syndrome depends on the frequency and spectrum of medical conditions requiring glucocorticoid treatment in a given population. Considerable variation in this frequency is observed in populations of different cultural and ethnic backgrounds.

International

In certain regions of the world (eg, Japan, Brazil), adrenal tumors are more frequently observed. Whether this and other aberrations are due to a genetically determined founder effect in a small subset of the population or whether environmental factors may be acting to increase patient risk is unknown.

Mortality/Morbidity

As a result of the multiple adverse effects of chronic glucocorticoid excess, both endogenous and exogenous Cushing syndrome are associated with significant morbidity. Untreated, they are also associated with an increased risk of premature death. Specific information about the effects of glucocorticoids on different systems is summarized in Table 2.

Sex

Endogenous Cushing syndrome of pituitary etiology is more prevalent in women than in men, with a female-to-male ratio of 9:1. Females are 8 times more likely than males to develop an ACTH-secreting pituitary adenoma and 3 times more likely to develop a cortisol-secreting adrenal tumor.

Age

Onset of endogenous Cushing syndrome of pituitary etiology occurs primarily in the third and fourth decades of life.

Previous
 
 
Contributor Information and Disclosures
Author

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, American College of Endocrinology

Disclosure: Nothing to disclose.

Coauthor(s)

Antony Lafferty, MB, BCh 

Antony Lafferty, MB, BCh is a member of the following medical societies: Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Received grant/research funds from Eli Lilly for pi; Received grant/research funds from NovoNordisk for pi; Received consulting fee from NovoNordisk for consulting; Partner received consulting fee from Onyx Heart Valve for consulting.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Thomas A Wilson, MD Professor of Clinical Pediatrics, Chief and Program Director, Division of Pediatric Endocrinology, Department of Pediatrics, The School of Medicine at Stony Brook University Medical Center

Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Pediatric Endocrine Society, Phi Beta Kappa

Disclosure: Nothing to disclose.

References
  1. Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am. 2011 Jun. 40(2):379-91, viii-ix. [Medline]. [Full Text].

  2. Liapi C, Chrousos GP. Glucocorticoids. Jaffe SJ, Aranda JV, eds. Therapeutic Principles in Practice. 2nd ed. Philadelphia, Pa: WB Saunders; 1992. 466-475.

  3. Lacroix A, N'Diaye N, Mircescu H, Hamet P, Tremblay J. Abnormal expression and function of hormone receptors in adrenal Cushing's syndrome. Endocr Res. 1998 Aug-Nov. 24(3-4):835-43. [Medline].

  4. Laue L, Loriaux DL, Chrousos GP. Glucocorticoid antagonists and the role of glucocorticoids at the resting and stress state. Adv Exp Med Biol. 1988. 245:225-35. [Medline].

  5. Dodt C, Wellhoner JP, Schutt M, Sayk F. [Glucocorticoids and hypertension.]. Internist (Berl). 2009 Jan. 50(1):36-41. [Medline].

  6. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet. 1998 Oct 2. 79(4):274-8. [Medline].

  7. Ragnarsson O, Glad CA, Bergthorsdottir R, Almqvist EG, Ekerstad E, Widell H, et al. Body composition and bone mineral density in women with Cushing's syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. Eur J Endocrinol. 2015 Jan. 172 (1):1-10. [Medline].

  8. Tritos NA, Biller BM. Advances in medical therapies for Cushing's syndrome. Discov Med. 2012 Feb. 13(69):171-9. [Medline].

  9. Rizk A, Honegger J, Milian M, Psaras T. Treatment Options in Cushing's Disease. Clin Med Insights Oncol. 2012. 6:75-84. [Medline]. [Full Text].

  10. Bansal V, El Asmar N, Selman WR, Arafah BM. Pitfalls in the diagnosis and management of Cushing's syndrome. Neurosurg Focus. 2015 Feb. 38 (2):E4. [Medline].

  11. Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Horm Res. 2009 Jan. 71 Suppl 1:99-104. [Medline].

  12. Keil MF, Merke DP, Gandhi R, Wiggs EA, Obunse K, Stratakis CA. Quality of life in children and adolescents one-year after cure of Cushing syndrome: A prospective study. Clin Endocrinol (Oxf). 2008 Dec 17. [Medline].

  13. Abad V, Chrousos GP, Reynolds JC, Nieman LK, Hill SC, Weinstein RS. Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat. J Bone Miner Res. 2001 Oct. 16(10):1879-85. [Medline].

  14. Agrons GA, Lonergan GJ, Dickey GE, Perez-Monte JE. Adrenocortical neoplasms in children: radiologic-pathologic correlation. Radiographics. 1999 Jul-Aug. 19(4):989-1008. [Medline]. [Full Text].

  15. Ansell BM. Overview of the side effects of corticosteroid therapy. Clin Exp Rheumatol. 1991 Jan-Feb. 9 Suppl 6:19-20. [Medline].

  16. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003 Dec. 88(12):5593-602. [Medline].

  17. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med. 1999 May 4. 130(9):759-71. [Medline]. [Full Text].

  18. Chrousos GP. Glucocorticoid therapy. Felig P, Frohman LA, eds. Endocrinology and Metabolism. New York, NY: McGraw-Hill, Inc; 2001. 609-632.

  19. Curtis JA, Cormode E, Laski B, Toole J, Howard N. Endocrine complications of topical and intralesional corticosteroid therapy. Arch Dis Child. 1982 Mar. 57(3):204-7. [Medline].

  20. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997 Jan 16. 336(3):172-7. [Medline].

  21. Hochberg Z, Lahav M, Shen-Orr Z, Benderli A, Barzilai D. Normal values of urinary-free cortisol in children and adolescents. Isr J Med Sci. 1983 Mar. 19(3):286-8. [Medline].

  22. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003 Aug. 24(4):523-38. [Medline]. [Full Text].

  23. Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med. 1990 Mar 15. 112(6):434-44. [Medline].

  24. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. 1999 Dec. 84(12):4317-23. [Medline].

  25. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res. 2007 Jan. 22(1):110-8. [Medline].

  26. Magiakou MA, Chrousos GP. Corticosteroid Therapy, Nonendocrine Disease, and Corticosteroid Withdrawal. Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6th ed. St. Louis, Mo: Mosby; 1997. 138-142.

  27. Magiakou MA, Mastorakos G, Chrousos GP. Cushing Syndrome: Differential Diagnosis and Treatment. Wierman ME, ed. Diseases of the Pituitary: Diagnosis and Treatment. Totowa, NJ: Humana Press; 1997. 179-202.

  28. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2006 Sep. 20(3):467-82. [Medline].

  29. Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab. 2005 May. 90(5):2531-6. [Medline]. [Full Text].

  30. Orth DN. Cushing's syndrome. N Engl J Med. 1995 Mar 23. 332(12):791-803. [Medline].

  31. Orth DN. Differential diagnosis of Cushing's syndrome. N Engl J Med. 1991 Sep 26. 325(13):957-9. [Medline].

  32. Orth DN, Kovacs WJ. The Adrenal Cortex. Wilson JD, Foster DW, Kronenberg H, Larsen PR, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: WB Saunders; 1998. 517-665.

  33. Papanicolaou DA, Chrousos GP. Cushing's Syndrome. Rakel RE, ed. Rakel's Current Therapy. Philadelphia, Pa: WB Saunders; 1999. 631-637.

  34. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child. 1982 Mar. 136(3):274-5. [Medline].

  35. Shepherd FA, Hoffert B, Evans WK, Emery G, Trachtenberg J. Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer. Arch Intern Med. 1985 May. 145(5):863-4. [Medline].

  36. Tsai M-J, Clark JH, Schrader WT. Mechanisms of action of Hormones that Act as Transcription-Regulatory factors. Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders; 1998. 55-95.

  37. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. 1993 May 5. 269(17):2232-8. [Medline].

 
Previous
Next
 
Diagnosis of Cushing syndrome.
Etiology of Cushing syndrome.
Physical findings in Cushing syndrome.
Table 1. Glucocorticoid Equivalencies [2]
Type Drug Dose Relative Glucocorticoid Potency Relative Mineralocorticoid Potency Plasma Half-Life



(mg)



Biologic Half-Life



(h)



Short-acting Cortisol 20 1.0 2 90 8-12
Hydrocortisone 25 0.8 2 80-118 8-12
Intermediate-acting Prednisone 5 4 1 60 18-36
Prednisolone 5 4 1 115-200 18-36
Triamcinolone 4 5 0 30 18-36
Methylprednisolone 4 5 0 180 18-36
Long-acting Dexamethasone 0.5 25-50 0 200 36-54
Betamethasone 0.6 25-50 0 300 36-54
Mineralocorticoid Aldosterone 0.3 0 300 15-20 8-12
Fludrocortisone 2 15 150 200 18-36
Desoxycorticosterone acetate 0 0 20 70
Table 2. Effects of Glucocorticoids During Long-Term Therapy
System Effects
Endocrine and metabolic Suppression of hypothalamic-pituitary-adrenal (HPA) axis (adrenal suppression)



Growth failure in children



Hyperinsulinemia/insulin resistance



Abnormal glucose tolerance test result/diabetes mellitus



GI Gastric irritation, peptic ulcer



Acute pancreatitis (rare, secondary to insulin resistance and hypertriglyceridemia)



Fatty infiltration of liver (hepatomegaly, rare)



Hemopoietic Leukocytosis



Neutrophilia - Increased recruitment from bone marrow, demargination, and decreased migration from blood vessels



Lymphopenia - Migration from blood vessels to lymphoid tissue



Eosinopenia



Monocytopenia



Immune Suppression of delayed (type IV) hypersensitivity (important with Mantoux testing for tuberculosis)



Inhibition of leukocyte and tissue macrophage migration



Inhibition of cytokine secretion/action



Suppression of the primary antigen response



Musculoskeletal Osteoporosis, spontaneous fractures



Avascular necrosis of femoral and humoral heads and other bones



Myopathy (particularly of the proximal muscles [eg, unable to comb hair or climb stairs])



Ophthalmic Posterior subcapsular cataracts (more common in children)



Elevated intraocular pressure/glaucoma



CNS (neuropsychiatric disorders) Sleep disturbances, insomnia (particularly with long-acting glucocorticoids and nocturnal dosing)



Euphoria, depression, mania, psychosis (more commonly observed in adults)



Obsessive behaviors (children with hypercortisolism are often more studious)



Pseudotumor cerebri (benign increase of intracranial pressure)



Cardiovascular[4] Hypertension[5]



Congestive heart failure in predisposed patients



Other cushingoid features Moon facies (broad cheeks with temporal muscle wasting) facial plethora



Generalized and truncal obesity (more marked in adults)



Supraclavicular fat collection



Posterior cervical fat deposition (dorsocervical hump)



Glucocorticoid-induced acne



Thin and fragile skin, violaceous striae (more common in adults)



Impotence, menstrual irregularity



Decreased thyroid-stimulating hormone and triiodothyronine



Hypokalemia (with very high cortisol levels or in the presence of potassium-wasting diuretics), metabolic alkalosis



Table 3. Genetic Causes of Cushing Syndrome
Cause Features Genetics
MEN1 Associated with pancreatic tumors producing gastrin, insulin, and/or ACTH that may metastasize to the liver;



multigland hyperparathyroidism, pituitary tumors, lipomas, and angiofibromas



11p13



(MIM 131100)



McCune-Albright syndrome Mosaic constitutively activating postzygotic GS alpha mutation that can lead to polyostotic fibrous dysplasia, pigmented skin lesions, gonadotropin-releasing hormone–independent precocious puberty, hyperthyroidism, renal phosphate wasting, and other endocrine and nonendocrine manifestations 20q13.2



(MIM 174800)



Beckwith-Wiedemann syndrome (Risk of adrenal malignancy) Macroglossia; visceromegaly; hyperinsulinemia; omphalocele; and risk of adrenal carcinoma, nephroblastoma, hepatoblastoma, rhabdomyosarcoma, and thoracic neuroblastoma requiring biannual sonograms 11p13



(MIM 130650)



Hemihypertrophy (Risk of adrenal malignancy) Adrenal tumors in association unilateral tissue overgrowth on ipsilateral or contralateral side



Compare upper and lower limbs and look for facial asymmetry



(MIM 235000)[6]
Li-Fraumeni syndrome (Risk of adrenal malignancy) Adrenal neoplasm



Personal or family history of multiple tumors (eg, lung, breast, nasopharynx, CNS, melanoma, pancreas, gonads, prostate)



17p13.1 -TP53 gene



22q12.1



(MIM 191170; 151623)



Carney complex Primary pigmented nodular adrenal disease (PPNAD); lentigines; myxomas of the heart, skin, and breast; melanotic schwannoma; growth hormone– and prolactin-secreting pituitary adenomas; Sertoli cell tumors of the testis; multiple small hypoechoic thyroid lesions; thyroid carcinoma 2p16 and 17q22-24



(MIM 605244; 160980)



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.